THRIVE
BIOSAFETY

Investor Presentation

July 2021

Disclosures

This Presentation (the “Presentation”) contains sensitive business and financial information. The sole purpose of this Presentation is to assist the recipient in deciding whether to proceed with a further inquiry of the Company. This Presentation does not purport to be all-inclusive or to necessarily contain all the information that a prospective investor may desire in evaluating a possible business transaction with the Company.

By accepting this Presentation, the recipient agrees to keep confidential the information contained herein or made available in connection with any further inquiry of the Company. This Presentation may not be photocopied, reproduced or distributed to others at any time without the prior written consent of. Upon request, the recipient will promptly return all materials received from the Company or (including this Presentation) without retaining any copies thereof.

This Presentation has been prepared for informational purposes relating to this transaction only and upon the express understanding that it will be used only for the purposes set forth above. The Company does not make any express or implied representation or warranty as to the accuracy or completeness of the information contained herein or made available in connection with any further investigation of the Company. The Company expressly disclaims any and all liability which may be based on such information, errors therein or omissions there from. The recipient shall be entitled to rely solely on the representations and warranties made to it in any definitive agreement and the due diligence that recipient conducts.

In furnishing this Presentation, the Company undertakes no obligation to provide the recipient with access to any additional information. This Presentation shall neither be deemed an indication of the state of affairs of the Company nor constitute an indication that there has not been any change in the Company or affairs of the Company since the date hereof.

This Presentation does not constitute an offer to sell or solicitation of an offer to buy securities in any jurisdiction where, or to any person to whom, it is unlawful to make such offer or solicitation in such jurisdiction.

This Presentation includes certain statements, estimates and projections with respect to the anticipated future performance of the Company. Such statements, estimates and projections are based on significant assumptions and subjective judgment concerning anticipated results. These assumptions and judgments are inherently subject to risks, variability and contingencies, many of which are beyond the Company’s control. These assumptions and judgments may or may not prove to be correct and there can be no assurance that any projected results are obtainable or will be realized. Actual results likely will vary from those projected, and such variations may be material. In addition, this Presentation does not describe certain risks associated with the Company’s business. All communications or inquires relating to the Company or this Presentation should be directed to the Company

Disclaimer / Safe Harbor

Disclaimer

This document is based on information provided by Thrive Biosafety (the "Company") and other sources that the Company believes are reliable. Nothing in this document is, or may be relied upon as, a promise or representation by the Company as to the past or the future information or results. This is not an offer or the solicitation of an offer to buy any securities of the Company, and readers should not construe the contents of this document as investment, legal or tax advice. The information contained in this document is made as of the date hereof and does not reflect any events that may occur subsequent to the date hereof. The Company undertakes no duty or obligation to update or revise the information included in this presentation.

Safe Harbor Statement

This presentation contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to a number of risks and uncertainties that may cause actual results to differ materially from those described in the forward-looking statements. These risks include, among others: general economic and business conditions; industry capacity; industry trends; competition; changes in business strategy or development plans; project performance; availability, terms, and deployment of capital; and availability of qualified personnel, as well as the risks and other factors set forth in our periodic filings with the U.S. Securities and Exchange Commission.

Forward Looking Statements

Statements made in this document may be forward-looking and therefore subject to various risks and uncertainties. The words "may", "will", "could", "should", "would", "suspect", "outlook", "believe", "plan", "anticipate", "estimate", "expect", "intend", "forecast", "objective", "hope" and "continue" (or the negative thereof), and words and expressions of similar import, are intended to identify forward-looking statements.

Certain material factors or assumptions are applied in making forward-looking statements and actual results may differ materially from those expressed or implied in such statements. Factors that could cause results to vary include those identified in the Company's filings with Canadian, United Kingdom and U.S. securities regulatory authorities. These factors include, but are not limited to our ability to enter into in-licensing, development, manufacturing and marketing and distribution agreements with other pharmaceutical, medical device, biotech, human tissue management or related companies and keep such agreements in effect; integration difficulties and other risks if we acquire or in-license technologies or product candidates; the product approval process is highly unpredictable; the timing of completion of clinical trials; reliance on third parties to manufacture our products; we may be subject to product liability claims; unexpected product safety or efficacy concerns may arise; the medical device industry is highly competitive; requirements for additional capital to fund future operations; dependence on key managerial personnel and external collaborators; no assurance that we will receive regulatory approvals in the United Kingdom, U.S., Canada or any other jurisdictions; various laws pertaining to health care fraud and abuse; reliance on the success of strategic investments and partnerships; the publication of negative results of clinical trials; unpredictable development goals and projected time frames; rising insurance costs; ability to enforce covenants not to compete; risks associated with the industry in which it operates; foreign currency risk; the potential violation of intellectual property rights of third parties; our efforts to obtain, protect or enforce our patents and other intellectual property rights related to our products; changes in the United Kingdom, U.S., Canadian or foreign patent law; inability to protect our trademarks from infringement; shareholders may be further diluted; volatility of our share price; a significant shareholder; we do not currently intend to pay dividends; we may be unsuccessful in evaluating material risks involved in complete and future acquisitions; we may be unable to identify, acquire or integrate acquisition targets successfully. Except as required by the United Kingdom, Canadian or U.S. securities laws, the Company does not undertake to update any forward-looking statements; such statements speak only as of the date made.

Notice of Confidentiality

This presentation contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to a number of risks and uncertainties that may cause actual results to differ materially from those described in the forward-looking statements. These risks include, among others: general economic and business conditions; industry capacity; industry trends; competition; changes in business strategy or development plans; project performance; availability, terms, and deployment of capital; and availability of qualified personnel, as well as the risks and other factors set forth in our periodic filings with the U.S. Securities and Exchange Commission.

Risk Factors

RISK FACTORS

Our Company is subject to all the same risks that all companies in this economy, are exposed to daily. These include risks relating to economic downturns, political and economic events, and technological developments (such as hacking and the ability to prevent hacking). Additionally, early-stage companies are inherently riskier than more developed companies. You should consider general risks as well as specific risks when deciding whether to invest.

New Company. Thrive is a new company. It has no history, no clients, no revenues. If you are investing in this Company, it's because you believe that Thrive will be able to, at some point time, market and sell biosafety as a service using the LDI Innovations Reader together with the qMLI synthetic receptor test for viruses. Further, we have never made a profit, and there is no assurance that we will ever be profitable

FDA and other governmental regulations. Our Thrive business model is subject to federal, state, and local laws and regulations, including the Federal Food and Drug Administration ("FDA"). We cannot proceed with human diagnostic testing until we receive either the FDA Emergency Use Authorization ("EUA") or FDA approval. Our Thrive virus test, powered by Qanik, collects individual healthcare information in real-time. Consequently, all aspects of our technology must comply with the Health Insurance Portability and Accountability Act of 1996 ("HIPPA"), including but not limited to the transfer of testing information to the test subject's cell phone, any centralized data collection, including cloud storage and the transmission of test data to state and federal officials for tracing, tracking and other pandemic response purposes. Compliance and or changes in existing laws or regulations could require material expenses and negatively affect our financial results through lower sales or higher costs.

Competition. The human diagnostic testing industry is highly competitive, including very large and very well-funded companies. In the Covid space, there are dozens of FDA EUAs currently authorized with more submissions to the FDA each week. Our test must be able to compete with the tests currently in the marketplace and in existing use. The existing tests that already have their EUA will make it more difficult for us to achieve market penetration, revenues, and profits.

Dependence on key personnel. Our performance depends significantly upon the continued contributions of our executive officers, the executive officers of Qanik, and a highly trained and deeply experienced scientific team located in Estonia. The Estonian team pioneered the virus testing technology and has continuing responsibilities for ensuring its reliability and relevance to the demands of the marketplace. These officers, scientists, and other key personnel have many years of experience in their respective roles, making it difficult to replace them. If we lose key personnel or cannot recruit qualified personnel, our operations and ability to manage our business may be adversely affected. We do not maintain key-man life insurance policies for our officers, directors, or key personnel.

Risk Factors Cont.

License to commercialize Qanik Intellectual Property. The Company is presently a small equity holder in Qanik, the owner of all intellectual property involved in the testing capability. Thrive does not own any of the intellectual property. Thrive holds a license of the technology for commercialization. Qanik will be solely responsible for defending against infringers and may not have the resources to mount a defense and enforce its patent. Also, no assurances can be given that the intellectual property of Qanik (i) will not infringe upon the intellectual property rights of others or (ii) that the patent and pending patent applications are valid or that they will be enforceable.

Thrive is a licensee of Qanik. The Company currently licenses its right to commercialize the technology from Qanik according to a binding and executed term sheet that can be renegotiated if the speed of regulatory approvals Thrive financing, the scaling of manufacturing, and a commercial rollout do not meet the expectations of the parties. Any of these contingencies could disrupt the agreed terms and cause us to lose our rights under that agreement.

Thrive has not fully paid the agreed Qanik. Thrive has only paid a small portion of its agreed licensing fee. If this or subsequent offerings do not raise enough capital, Thrive may not be able to pay the required fee and lose its license.

The current valuation of the Company is difficult to assess. Unlike publicly traded companies that list their shares on a stock exchange resulting in market-driven stock prices, the valuation of private companies, especially startups, is difficult to assess, and you may risk overpaying for your investment. If and when the Company undertakes additional rounds of equity financing, your ownership interest in the Company represented by the shares you own will be diluted. As a percentage, you will own less of the Company as a result of each new round of capital raised.

Our investor presentation includes financial projections over the next twelve months. Our projections are the opinion of management regarding our ability to market and generate sales for our products and services. There are no assurances we will be able to achieve the revenue goals represented in those projections.

The auditor has included a "going concern" note in the financial statements. We may not have enough funds to sustain the business until it becomes profitable. Even if we raise funds through this Regulation CF crowdfunding round plus a Regulation A offering in the future, we may not accurately anticipate how quickly we may use the funds and if it is sufficient for our business to achieve profitability.

The Company will likely need more money. In this and its subsequent offerings, the Company might not sell enough shares to meet its operating needs or fulfill its plans. In this case, the Company may cease operating, including liquidating its assets and losing its license to intellectual property, which could lead to the total loss of your investment. Even if it sells all the common stock it's offering now, it will probably need to raise more funds in the future, and if it can't get them, the business could fail. Even if the Company does make a successful offering in the future, the terms of that offering might result in your investment in the Company being valued less. Later investors may get better terms, and the issuance of their shares may dilute your ownership.

You can't easily resell the securities. There are restrictions on how you can resell your securities. More importantly, there is currently no market for these securities. There might never be one. The Company may not achieve its goal of going public or get acquired by another company. That means the money you paid for these securities could be tied up for a long time.

You may have difficulty depositing your shares. Even if the Company successfully lists its shares to a stock exchange, you may have difficulty depositing your shares with a broker. Many licensed broker-dealers refuse to deposit shares listed on the Over The Counter ("OTC") exchange. The Company may need to raise enough capital to list to a major exchange for you to deposit your shares easily. The listing requirements of major exchanges are more difficult to achieve, and the Company may fail to meet those requirements.

Overview

Thrive Testing & Biosafety, Inc. ("Thrive") is an equity stakeholder and U.S. Western States licensee of testing technology developed by Qanik DX, Inc. ("Qanik") with an option to license the remaining U.S. states. This internationally patented test represents the culmination of years of R&D and combines advances in biochemistry, nanotechnology, and photonics. The test detects targeted viruses in as little as 15 seconds by using nanotechnology to create "smart" synthetic receptors that bind with specific target spike proteins of a virus. A chemical reaction occurs when an individual virus protein binds with a receptor, emitting light that the photon detector (the "Reader") can measure bind reactions over the course of 15 seconds. This sensitivity to low levels of virus means the potential for **Asymptomatic Detection**.





Overview Cont.

Initially developed to target hormones and later HIV, the test identifies viruses in saliva, blood, and mucus samples. The test can reveal the presence of the SARS-CoV-2 virus in human saliva. Lab results have validated the test detects extremely low viral loads. We intend to validate early, pre-symptomatic detection, a critical step in reducing the spread of any form of virus. Human diagnostic testing in the United States requires an Emergency Use Authorization ("EUA") or approval by the Food and Drug Administration ("FDA").

- Please sign up or check for updates on progress toward the FDA EUA.
- (See "Our Timeline for Commercialization" below.)

Other Locations for Testing

- Through our initial investors we have access to countries worldwide. We project that equipment and tests will be ready for commercial use in the fall of 2021. It is our intention to begin testing as soon as possible. If we are experiencing delays in receiving the FDA EUA, the following countries are potential sites for the first Thrive tests: Australia, New Zealand, the Philippines, Singapore, Vietnam, Thailand, India and Costa Rica.



Portable “Lab-on-the-Go”

The Challenge

There are many forms of viruses that are deadly to human beings. The list includes Marburg, Ebola, HIV, Hantavirus, Influenza, Dengue, Rotavirus, MERS-CoV, SARS-CoV, and our ongoing pandemic due to SARS-CoV-2 ("Covid19"). Currently, the world is facing wave after wave of Covid19 and its many variants as countries struggle to adapt. Millions of people have died, including over 575,000 in the US alone. Despite over 140 million fully vaccinated in the US to date, the virus continues to mutate into new forms contributing to an ongoing daily count of over 15,000 new cases every day in the US. Many countries worldwide have seen significant economic damage, as well.

The following excerpt is from the August 18, 2020 publication in the *Annals of Internal Medicine.* The notation "CI" is the "confidence interval" means the true result lies in between the stated range.

Results:

Over the 4 days of infection before the typical time of symptom onset (day 5), the probability of a false-negative result in an infected person decreases from 100% (95% CI, 100% to 100%) on day 1 to 67% (CI, 27% to 94%) on day 4. On the day of symptom onset, the median false-negative rate was 38% (CI, 18% to 65%). This decreased to 20% (CI, 12% to 30%) on day 8 (3 days after symptom onset) then began to increase again, from 21% (CI, 13% to 31%) on day 9 to 66% (CI, 54% to 77%) on day 21. https://www.acpiournals.org/doi/full/10.7326/M20-1495



The Opportunity

The world needs a highly accurate, fast, cheap test that can provide immediate results and reveal virus presence within the first 48 hours of exposure. Early detection allows quarantine before a person becomes contagious.

Thrive BioTest™

The Thrive BioTest™ test, administered in less than a minute, is highly accurate and can detect extremely low levels of live virus in a saliva sample. This provides the world with the test it needs to reopen safely and, with continuous testing, stay that way.

Qanik can adapt its virus test to detect all forms of viruses, known and yet to be discovered, on surfaces and in human beings. Thrive, the Qanik licensee will bring those tests to the people and places in need in the United States.



The Competition

The current "gold standard" in testing is a molecular test called polymerase chain reaction ("PCR"). This approach amplifies strands of viral DNA in a sample to allow detection. Developed forty years ago and a breakthrough at the time, molecular tests have a well-known limitation, as described in "The Challenge" above. Antigen tests are another form of testing that uses diagnostic proteins to identify viruses. Antigen tests are rapid (15 minutes) but not sensitive enough to be used as an accurate or early diagnostic indicator. The Thrive Biopass™ powered by Qanik DX represents an evolutionary leap in testing.

	Qanik DX – QT Sensor and Cartridge	1. Antibody Detection Systems	2. Artificial Antibody Detection	3. Isothermal PCR Amplification
THRIVE point of care or entry	✓	✗	✗	✗
Direct detection of the CoVid virus	✓	✗	✗	✗
Rapid test, one minute or less	✓	✗	✗	✗
Low levels of virus detected	✓	✗	✗	✗
Cost ~ $50.00 (USD) and less upon scale	✓	✗	✗	✗
Low false-negative error rate	✓	✓	✓	✗
Realtime tracking to the cloud	✓	✗	✗	✗

1. Antibody Detection is the process of analyzing the immune system response to the virus after viral reproduction has begun. In other words, it only diagnoses the presence of a COVID-19 infection once the person has already developed the systemic disease and is contagious.

2. Artificial Antibodies: This form of testing is based on the binding of artificial antibodies with the virus itself (variations of ELISA method). This method requires producing quite a significant amount of artificial antibodies, which is costly.

3. RNA - PCR Methods are based on the detection of the virus RNA chain copies using isothermal PCR amplification methods. While the response time of the method is short (below 20 minutes), these tests are known to produce high false-negative rates.

The Product

Thrive's "Lab on the Go" system includes the internationally patented Quantum Labeled Molecular Interaction technology ("qMLI"). It can test for specific viruses using saliva in under 1 minute and prior to symptoms. Additionally, Thrive BioTest™ has an extremely low virus load Level of Detection (LOD) capability. Using our encrypted infrastructure, test results flow seamlessly from the photonic reader to technician's table and the test subject's smart phone. When needed and agreed to by the test subject, Thrive can also send the test results to a healthcare provider, place of employment or government agency for tracing and tracking of an outbreak. These are critical steps in stopping the spread of any virus-related disease, saving lives, and keeping businesses open. The Thrive BioTest™ is perfect as a mass testing tool at hospitals, clinics, airports, hotels, schools, concerts, and any other venue where people want to gather in large numbers.

- Based on our evolving understanding of Covid, a negative test result will grant each user a 24 to 48-hour Thrive BioClear™, enabling the user to enter any Thrive Biosafety Partner area, event, or place of business.
- The Qanik DX/Thrive Biotest™ has been extensively vetted in the lab and in the field. As part of the European Union's biodefense readiness, the photonic reader has been used to detect organic compounds and bacteria by the EU military alliance.



The Market

The licensed territory for Thrive is the western eleven states of the United States. We have targeted the testing needs of the Hawaiian Islands and Washington State as our first two markets. We are looking more specifically at three potentials: television and film production, sporting and cultural events, and airport departures/arrivals. Our first customer, a testing company based in Honolulu, will add the Thrive Test as a testing method upon an issuance of the FDA's EUA.

There are many potential customers for Thrive Test inside the states of Hawaii and Washington, including hotels, cruise lines, schools, large corporate campuses, and event centers. Even with vaccinations, fast and accurate testing will be vital to the United States and the world's continued reopening and returning to everyday activities.

The Covid Tracking Project chart below shows the millions of Covid tests administered in the U.S. from March 3, 2020 to March 4, 2021



Timeline for Commercialization

July 1, 2021	August 15, 2021	September 15, 2021	October 1, 2021	October 15, 2021
FDA EUA • ***Pre-submission of the testing technology by Qanik DX, Inc. Engineering design work underway at MPR***	FDA EUA • ***Final submission to the FDA for Emergency Use Authorization.*** • ***First Reader shipped to Thrive Biosafety***	ThriveTest™ • ***EUA issued (see NOTE below) Up to 1,500 tests per day begins in the Hawaiian Islands in partnership with V2 Safe Solutions'"***	Testing • ***Increase testing to 3,000 tests per day in the Hawaiian Islands. Additional Photonic Readers and test shipped to first mainland sites***	Testing • ***Increase testing to 5,000 tests per day in the Hawaiian Islands and first mainland test sites***

NOTE: An FDA Emergency Use Authorization ("EUA") is required before any testing can begin. Thrive can not guarantee an FDA EUA can or will ever be issued for this form of testing technology.

Offering Terms

- Offering Amount: $5,000,000
- Securities Offered: Common Stock
- Total Shares Offered: 12,500,00 Shares
- Price Per Share: $0.40
- Minimum Purchase Amount: $200.00
- Intended IPO: Projected 4th Quarter 2021
- Current Issued Shares*: 26,500,00

*assuming fully subscribed Seed Round B